Tiago R Marques

List of Publications by Year
in descending order

118 papers	8,086 citations

71102
41 h-index

53230
85 g-index

123 all docs	123 docs citations
123 times ranked	10337 citing authors

#	Article	IF	Citations
1	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry, 2017, 174, 216-229.	7.2	685
2	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	1.3	627
3	Schizophreniaâ€"An Overview. JAMA Psychiatry, 2020, 77, 201.	11.0	569
4	High-potency cannabis and the risk of psychosis. British Journal of Psychiatry, 2009, 195, 488-491.	2.8	465
5	Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry,the, 2015, 2, 233-238.	7.4	429
6	Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users. Schizophrenia Bulletin, 2014, 40, 1509-1517.	4.3	364
7	The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Molecular Psychiatry, 2017, 22, 666-679.	7.9	347
8	Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment. Schizophrenia Research, 2010, 116, 234-242.	2.0	253
9	Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis. Schizophrenia Bulletin, 2015, 41, 1162-1170.	4.3	223
10	Confirmation that the AKT1 (rs2494732) Genotype Influences the Risk of Psychosis in Cannabis Users. Biological Psychiatry, 2012, 72, 811-816.	1.3	212
11	Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychological Medicine, 2016, 46, 3231-3240.	4.5	202
12	Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures. Molecular Psychiatry, 2019, 24, 549-561.	7.9	179
13	An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis. Biological Psychiatry, 2017, 81, 470-477.	1.3	176
14	Neuroinflammation in schizophrenia: meta-analysis of *in vivo* microglial imaging studies. Psychological Medicine, 2019, 49, 2186-2196.	4.5	151
15	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nature Communications, 2020, 11, 246.	12.8	148
16	White matter integrity as a predictor of response to treatment in first episode psychosis. Brain, 2014, 137, 172-182.	7.6	130
17	Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode. American Journal of Psychiatry, 2019, 176, 811-819.	7.2	123
18	Social Disadvantage: Cause or Consequence of Impending Psychosis?. Schizophrenia Bulletin, 2013, 39, 1288-1295.	4.3	114

#	Article	IF	Citations
19	Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophrenia Research, 2010, 119, 75-78.	2.0	112
20	Cortical Folding Defects as Markers of Poor Treatment Response in First-Episode Psychosis. JAMA Psychiatry, 2013, 70, 1031.	11.0	104
21	Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis. Psychological Medicine, 2011, 41, 463-476.	4.5	102
22	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. Brain, 2015, 138, 3003-3015.	7.6	100
23	Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients. Psychological Medicine, 2012, 42, 1893-1901.	4.5	97
24	Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. Human Brain Mapping, 2013, 34, 272-282.	3.6	97
25	Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. Brain, 2015, 138, 3016-3029.	7.6	90
26	Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies. Journal of Neural Transmission, 2019, 126, 1637-1651.	2.8	84
27	Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatrica Scandinavica, 2018, 137, 39-46.	4.5	76
28	Using Machine Learning and Structural Neuroimaging to Detect First Episode Psychosis: Reconsidering the Evidence. Schizophrenia Bulletin, 2020, 46, 17-26.	4.3	76
29	Genetic variants associated with longitudinal changes in brain structure across the lifespan. Nature Neuroscience, 2022, 25, 421-432.	14.8	75
30	Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. American Journal of Human Genetics, 2016, 98, 735-743.	6.2	65
31	Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry,the, 2016, 3, 1115-1128.	7.4	59
32	Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region With Cortical and Subcortical Morphology and Cognition. JAMA Psychiatry, 2020, 77, 420.	11.0	54
33	GABA-A receptor differences in schizophrenia: a positron emission tomography study using [11C]Ro154513. Molecular Psychiatry, 2021, 26, 2616-2625.	7.9	53
34	Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. Journal of Psychopharmacology, 2015, 29, 892-897.	4.0	51
35	Kinetic modelling of [11C]PBR28 for 18‰kDa translocator protein PET data: A validation study of vascular modelling in the brain using XBD173 and tissue analysis. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1227-1242.	4.3	51
36	Brain Blood Flow SPET Imaging in Heroin Abusers. Annals of the New York Academy of Sciences, 2006, 1074, 466-477.	3.8	50

#	Article	IF	Citations
37	Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. Journal of Nuclear Medicine, 2014, 55, 595-601.	5.0	50
38	In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis. JAMA Psychiatry, 2019, 76, 1074.	11.0	50
39	Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia. Molecular Psychiatry, 2020, 25, 584-602.	7.9	49
40	Globally Efficient Brain Organization and Treatment Response in Psychosis: A Connectomic Study of Gyrification. Schizophrenia Bulletin, 2016, 42, 1446-1456.	4.3	47
41	Effect of high-potency cannabis on corpus callosum microstructure. Psychological Medicine, 2016, 46, 841-854.	4.5	47
42	Connectomic correlates of response to treatment in first-episode psychosis. Brain, 2017, 140, 487-496.	7.6	47
43	The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis. Molecular Psychiatry, 2021, 26, 1310-1320.	7.9	47
44	Sexual dysfunction in people with prodromal or first-episode psychosis. British Journal of Psychiatry, 2012, 201, 131-136.	2.8	46
45	Power calculations for multicenter imaging studies controlled by the false discovery rate. Human Brain Mapping, 2010, 31, 1183-1195.	3.6	43
46	The practical management of refractory schizophrenia - the Maudsley Treatment REview and Assessment Team service approach. Acta Psychiatrica Scandinavica, 2014, 130, 427-438.	4.5	38
47	Impaired theta phase coupling underlies frontotemporal dysconnectivity in schizophrenia. Brain, 2020, 143, 1261-1277.	7.6	38
48	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. Journal of the Neurological Sciences, 2016, 368, 243-248.	0.6	37
49	Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis. Psychoneuroendocrinology, 2019, 99, 145-153.	2.7	36
50	Effects of antipsychotics on cortisol, interleukin-6 and hippocampal perfusion in healthy volunteers. Schizophrenia Research, 2016, 174, 99-105.	2.0	34
51	The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychological Medicine, 2011, 41, 1481-1488.	4.5	33
52	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [^{11}C]IMA107. American Journal of Psychiatry, 2016, 173, 714-721.	7.2	33
53	The neuro/PsyGRID calibration experiment. Human Brain Mapping, 2012, 33, 373-386.	3.6	30
54	Clinical utility of magnetic resonance imaging in first-episode psychosis. British Journal of Psychiatry, 2017, 211, 231-237.	2.8	30

#	Article	IF	Citations
55	Reduced mu opioid receptor availability in schizophrenia revealed with [11C]-carfentanil positron emission tomographic Imaging. Nature Communications, 2019, 10, 4493.	12.8	30
56	Effects of copy number variations on brain structure and risk for psychiatric illness: Large‑scale studies from the<scp>ENIGMA</scp>working groups on<scp>CNVs</scp>. Human Brain Mapping, 2022, 43, 300-328.	3.6	30
57	Obsessive–compulsive disorder as a visual processing impairment. Medical Hypotheses, 2010, 74, 107-109.	1.5	29
58	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Translational Psychiatry, 2021, 11, 393.	4.8	27
59	A Neuroanatomical Signature for Schizophrenia Across Different Ethnic Groups. Schizophrenia Bulletin, 2015, 41, 1266-1275.	4.3	26
60	1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans. Translational Psychiatry, 2021, 11, 182.	4.8	24
61	Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis. NPJ Schizophrenia, 2020, 6, 21.	3.6	23
62	Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis. Psychological Medicine, 2021, 51, 340-350.	4.5	23
63	The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry, 2013, 13, 320.	2.6	21
64	Effects of aripiprazole and haloperidol on neural activation during the n-back in healthy individuals: A functional MRI study. Schizophrenia Research, 2016, 173, 174-181.	2.0	20
65	An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortium. Psychological Medicine, 2020, 50, 2034-2045.	4.5	18
66	Assessment of the impact of the scanner-related factors on brain morphometry analysis with Brainvisa. BMC Medical Imaging, 2011, 11, 23.	2.7	17
67	Role of Environmental Confounding in the Association between FKBP5 and First-Episode Psychosis. Frontiers in Psychiatry, 2014, 5, 84.	2.6	17
68	Cortisol awakening response is decreased in patients with first-episode psychosis and increased in healthy controls with a history of severe childhood abuse. Schizophrenia Research, 2019, 205, 38-44.	2.0	17
69	The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project. Schizophrenia Research, 2018, 195, 306-317.	2.0	17
70	Structural Covariance of Cortical Gyrification at Illness Onset in Treatment Resistance: A Longitudinal Study of First-Episode Psychoses. Schizophrenia Bulletin, 2021, 47, 1729-1739.	4.3	16
71	Jumping to conclusions at first onset of psychosis predicts longer admissions, more compulsory admissions and police involvement over the next 4 years: the GAP study. Psychological Medicine, 2019, 49, 2256-2266.	4.5	14
72	How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses. European Neuropsychopharmacology, 2014, 24, 1279-1288.	0.7	13

#	Article	IF	Citations
73	Cortical thickness correlates of minor neurological signs in patients with first episode psychosis. Schizophrenia Research, 2018, 200, 104-111.	2.0	13
74	Dopamine, Striatum, Antipsychotics, and Questions About Weight Gain. JAMA Psychiatry, 2016, 73, 107.	11.0	12
75	Dynamic and Static Cognitive Deficits in Schizophrenia and Bipolar Disorder After the First Episode. Schizophrenia Bulletin, 2022, 48, 590-598.	4.3	12
76	Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 677-687.	3.2	11
77	â€œI am sane but he is madâ€: Insight and illness attributions to self and others in psychosis. Psychiatry Research, 2013, 207, 173-178.	3.3	10
78	The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study. Molecular Psychiatry, 2021, 26, 4464-4474.	7.9	10
79	SatisfaÃ§Ã£o com a Especialidade entre os Internos da FormaÃ§Ã£o EspecÃfica em Portugal. Acta Medica Portuguesa, 2015, 28, 209-221.	0.4	9
80	Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An in vivo PET Study With Neuropathological Comparison. Frontiers in Neurology, 2020, 11, 541377.	2.4	9
81	Sexual dysfunction and central obesity in patients with first episode psychosis. European Psychiatry, 2017, 42, 1-7.	0.2	8
82	Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study. Psychopharmacology, 2022, 239, 3439-3445.	3.1	8
83	Utilising symptom dimensions with diagnostic categories improves prediction of time to first remission in first-episode psychosis. Schizophrenia Research, 2018, 193, 391-398.	2.0	7
84	Translation and cross-cultural adaptation of the Sexual Function Questionnaire (SFQ) into Brazilian Portuguese. Trends in Psychiatry and Psychotherapy, 2017, 39, 110-115.	0.8	6
85	The association of psychosocial risk factors for mental health with a brain marker altered by inflammation: A translocator protein (TSPO) PET imaging study. Brain, Behavior, and Immunity, 2019, 80, 742-750.	4.1	6
86	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. British Journal of Psychiatry, 2022, 221, 740-747.	2.8	6
87	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. Biological Psychiatry, 2019, 85, e35-e39.	1.3	5
88	Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper. Drug Safety, 2021, 44, 825-834.	3.2	5
89	117.4 Pet Imaging of Neuroinflammation in Schizophrenia. Schizophrenia Bulletin, 2017, 43, S64-S65.	4.3	4
90	Parametric Mapping for TSPO PET Imaging with Spectral Analysis Impulsive Response Function. Molecular Imaging and Biology, 2021, 23, 560-571.	2.6	4

#	Article	IF	Citations
91	Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3530-3539.	6.4	4
92	Mental health risk factors during the first wave of the COVID-19 pandemic. BJPsych Open, 2021, 7, e195.	0.7	4
93	Acute acetate administration increases endogenous opioid levels in the human brain: A [^{11}C]carfentanil molecular imaging study. Journal of Psychopharmacology, 2021, 35, 606-610.	4.0	3
94	Association between the COMT gene and neurological abnormalities and poorer executive function in psychosis. Psychiatry Research, 2015, 230, 742-743.	3.3	2
95	F180. CANNABINOID 1 RECEPTOR AVAILABILITY & MEMORY FUNCTION IN FIRST EPISODE PSYCHOSIS: A MULTI-MODAL PET-FMRI STUDY. Schizophrenia Bulletin, 2018, 44, S291-S291.	4.3	2
96	Translation and cross-cultural adaptation of the Arizona Sexual Scale (ASEX) into Portuguese. Trends in Psychiatry and Psychotherapy, 2019, 41, 247-253.	0.8	2
97	32.4 A NOVEL TREATMENT FOR COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA BY ENHANCING THE ACTIVITY OF PARVALBUMIN INTERNEURONS. Schizophrenia Bulletin, 2019, 45, S142-S143.	4.3	2
98	The National Student Survey: validation in Portuguese medical students. Assessment and Evaluation in Higher Education, 2019, 44, 66-79.	5.6	2
99	Effects of aripiprazole and haloperidol on neural activation during a simple motor task in healthy individuals: A functional MRI study. Human Brain Mapping, 2017, 38, 1833-1845.	3.6	1
100	F229. Cannabinoid 1 Receptor and Memory Function in First Episode Psychosis: A Multi-Modal PET-fMRI Study. Biological Psychiatry, 2018, 83, S327-S328.	1.3	1
101	Commentary: A Position Statement on Sexual Orientation Conversion Therapies by Members of the Board of Directors of the Portuguese Society of Clinical Sexology (SPSC). International Journal of Sexual Health, 2019, 31, 231-232.	2.3	1
102	Treatment of First-Episode Schizophrenia in a Young Woman. JAMA Psychiatry, 2020, 77, 211.	11.0	1
103	T45. THE EFFICACY AND HETEROGENEITY OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA: A META-ANALYSIS. Schizophrenia Bulletin, 2020, 46, S248-S249.	4.3	1
104	Antipsychotics, versatility in action. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	1
105	THE EFFECTS OF HALOPERIDOL AND ARIPIPRAZOLE ON RESTING STATE BRAIN PERFUSION IN HEALTHY VOLUNTEERS. Schizophrenia Research, 2010, 117, 238-239.	2.0	0
106	DOES STRESS CONTRIBUTE TO INFLAMMATORY AND METABOLIC ABNORMALITIES IN FIRST EPISODE PSYCHOSIS?. Schizophrenia Research, 2010, 117, 369-370.	2.0	0
107	WHITE MATTER TRACTS AS PREDICTORS OF TREATMENT OUTCOME. Schizophrenia Research, 2010, 117, 459.	2.0	0
108	Authors' reply. British Journal of Psychiatry, 2017, 211, 250-250.	2.8	0

#	Article	IF	Citations
109	F68. PREMORBID IQ, EDUCATIONAL LEVEL AND JUMPING TO CONCLUSIONS AS PREDICTORS OF CLINICAL OUTCOME AT FIRST ONSET OF PSYCHOSIS OVER THE NEXT 4 YEARS: THE GAP STUDY. Schizophrenia Bulletin, 2018, 44, S246-S246.	4.3	0
110	O6.7. COMMON NEUROANATOMICAL ABNORMALITIES IN FIRST EPISODE PSYCHOSIS ACROSS SEVERAL INDEPENDENT SAMPLES. Schizophrenia Bulletin, 2018, 44, S92-S92.	4.3	0
111	O2.4. THE MISSING PIECE IN THE PUZZLE: COGNITIVE DECLINE IN SCHIZOPHRENIA AND BIPOLAR PATIENTS AFTER THE FIRST EPISODE. Schizophrenia Bulletin, 2018, 44, S77-S77.	4.3	0
112	O8.7. COGNITIVE SUBTYPES IN FIRST-EPISODE PSYCHOSIS AND ASSOCIATION TO TREATMENT RESPONSE. Schizophrenia Bulletin, 2018, 44, S98-S99.	4.3	0
113	O7.6. GABAA RECEPTOR AVAILABILITY IN PATIENTS WITH SCHIZOPHRENIA: A PET STUDY USING [11C]-RO15. Schizophrenia Bulletin, 2019, 45, S181-S182.	4.3	0
114	F80. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS: PET AND MR IMAGING FINDINGS IN FIRST EPISODE AND CHRONIC SCHIZOPHRENIA. Schizophrenia Bulletin, 2019, 45, S284-S284.	4.3	0
115	S153. IMPAIRED THETA PHASE-COUPLING BETWEEN HIPPOCAMPUS AND MEDIAL PREFRONTAL CORTEX IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S94-S94.	4.3	0
116	S186. THE EFFECTS OF CHILDHOOD TRAUMA ON HIPPOCAMPAL VOLUME IN FIRST EPISODE PSYCHOSIS: DOES CORTISOL PLAY A ROLE?. Schizophrenia Bulletin, 2020, 46, S109-S109.	4.3	0
117	O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS. Schizophrenia Bulletin, 2020, 46, S28-S28.	4.3	0
118	O5.5. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: MULTI-MODAL PET AND FMRI FINDINGS. Schizophrenia Bulletin, 2020, 46, S12-S13.	4.3	0